{"id":"placebo-fulvestrant-goserelin-acetate","safety":{"commonSideEffects":[{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Vaginal dryness"},{"rate":null,"effect":"Arthralgia"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fulvestrant is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-driven growth in hormone receptor-positive breast cancer. Goserelin is a GnRH agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased estrogen and progesterone production in premenopausal women. Together, they provide dual hormonal blockade to prevent cancer cell proliferation.","oneSentence":"This combination uses fulvestrant to block estrogen receptors in cancer cells and goserelin to suppress ovarian hormone production, while placebo serves as a control arm.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:51:28.027Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in premenopausal women"}]},"trialDetails":[{"nctId":"NCT01942135","phase":"PHASE3","title":"Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-09-26","conditions":"Metastatic Breast Cancer","enrollment":521},{"nctId":"NCT03447132","phase":"PHASE3","title":"Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant","status":"COMPLETED","sponsor":"International Cancer Research Group, United Arab Emirates","startDate":"2017-12-20","conditions":"Breast Neoplasm Female","enrollment":354},{"nctId":"NCT05438810","phase":"PHASE3","title":"This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.","status":"UNKNOWN","sponsor":"Ahon Pharmaceutical Co., Ltd.","startDate":"2022-01-18","conditions":"Advanced Breast Cancer, Female Breast Cancer","enrollment":312}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo,Fulvestrant,Goserelin acetate","genericName":"Placebo,Fulvestrant,Goserelin acetate","companyName":"Ahon Pharmaceutical Co., Ltd.","companyId":"ahon-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses fulvestrant to block estrogen receptors in cancer cells and goserelin to suppress ovarian hormone production, while placebo serves as a control arm. Used for Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in premenopausal women.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}